210 related articles for article (PubMed ID: 32730257)
1. Association between proton pump inhibitor use and risk of fracture: A population-based case-control study.
Kim JJ; Jang EJ; Park J; Sohn HS
PLoS One; 2020; 15(7):e0235163. PubMed ID: 32730257
[TBL] [Abstract][Full Text] [Related]
2. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
3. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes.
Chou YS; Jiang HJ; Chen CH; Ho PS; Lee TC
Sci Rep; 2020 Aug; 10(1):14081. PubMed ID: 32826941
[TBL] [Abstract][Full Text] [Related]
6. Impact of bisphosphonate compliance on the risk of osteoporotic fracture in France.
Belhassen M; Cortet B; Confavreux CB; Lamezec L; Ginoux M; Van Ganse E
Arch Osteoporos; 2018 Oct; 13(1):113. PubMed ID: 30341636
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates Use and Risk of Subtrochanteric and Diaphyseal Femur Fractures in Korea: Results from the National Claim Registry.
Lee YK; Byun DW; Jung SM; Kwon HY; Kim HY; Kim SH; Kim TY; Jang S; Ha YC
Calcif Tissue Int; 2019 Mar; 104(3):313-319. PubMed ID: 30446771
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease-a nested case-control study.
Torvinen-Kiiskinen S; Tolppanen AM; Koponen M; Tanskanen A; Tiihonen J; Hartikainen S; Taipale H
Aliment Pharmacol Ther; 2018 Apr; 47(8):1135-1142. PubMed ID: 29508411
[TBL] [Abstract][Full Text] [Related]
9. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitor use and the risk of fractures among an older adult cohort.
Harding BN; Weiss NS; Walker RL; Larson EB; Dublin S
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):596-603. PubMed ID: 29493043
[TBL] [Abstract][Full Text] [Related]
11. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
12. Long-term proton pump inhibitor therapy and risk of hip fracture.
Yang YX; Lewis JD; Epstein S; Metz DC
JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
Yu EW; Bauer SR; Bain PA; Bauer DC
Am J Med; 2011 Jun; 124(6):519-26. PubMed ID: 21605729
[TBL] [Abstract][Full Text] [Related]
14. Population-based Analysis for Risk of Suicide Death in Elderly Patients after Osteoporotic Fracture: a Nested Case-Control Study.
Jang SY; Cha Y; Lee JC; Kim H; Kim KJ; Choy W
J Korean Med Sci; 2021 Sep; 36(36):e225. PubMed ID: 34519185
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of appendectomy in patients with gastroesophageal reflux disease: A nested case-control study using a national sample cohort.
Kim SY; Kim HJ; Lim H; Lim MS; Kim M; Choi HG
Medicine (Baltimore); 2018 Dec; 97(52):e13700. PubMed ID: 30593140
[TBL] [Abstract][Full Text] [Related]
16. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
[TBL] [Abstract][Full Text] [Related]
17. Oral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from Korea.
Jung SY; Sohn HS; Park EJ; Suh HS; Park JW; Kwon JW
PLoS One; 2016; 11(3):e0150531. PubMed ID: 26937968
[TBL] [Abstract][Full Text] [Related]
18. Use of proton pump inhibitors and risk of osteoporosis-related fractures.
Targownik LE; Lix LM; Metge CJ; Prior HJ; Leung S; Leslie WD
CMAJ; 2008 Aug; 179(4):319-26. PubMed ID: 18695179
[TBL] [Abstract][Full Text] [Related]
19. Chronic proton pump inhibitor therapy and the risk of colorectal cancer.
Yang YX; Hennessy S; Propert K; Hwang WT; Sedarat A; Lewis JD
Gastroenterology; 2007 Sep; 133(3):748-54. PubMed ID: 17678926
[TBL] [Abstract][Full Text] [Related]
20. Saving bones without risking brain-bisphosphonates and risk of stroke: matched case-control study.
Asghar ZB; Godoy Caballero A; Pathirannehelage S; Williams J; McKay S; Grassby P; de Lusignan S; Niroshan Siriwardena A
Osteoporos Int; 2019 Sep; 30(9):1845-1854. PubMed ID: 31214750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
